Clinical Trials on NK Cell Mediated Immunity in Singapore

Total 4 results

National Cancer Centre, Singapore

Terminated

Bortezomib With Combination of Gemcitabine, Ifosfamide and Oxaliplatin in Untreated NK/T Cell Lymphoma (Gifox-B)

Extranodal NK-T-CELL LYMPHOMA

Singapore
National Cancer Centre, Singapore
Bristol-Myers Squibb

Withdrawn

Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma

NK/T Cell Lymphoma

Singapore
National Cancer Institute (NCI)

Active, not recruiting

Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma

Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma | Recurrent Nasopharyngeal Undifferentiated Carcinoma | Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 | Adult Nasal Type Extranodal NK/T-Cell Lymphoma | Stage IV Nasopharyngeal Undifferentiated Carcinoma...

United States, Singapore, Japan, Hong Kong
Singapore General Hospital

Completed

Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma

Angioimmunoblastic T-cell Lymphoma | Hepatosplenic T-cell Lymphoma | Peripheral T-cell Lymphoma (Not Otherwise Specified) | Extranodal NK/T-cell Lymphoma Nasal Type | Enteropathy- Type T-cell Lymphoma | Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative) | Relapsed ALCL (ALK-1 Positive) Post...

Singapore, Malaysia, Korea, Republic of

3

Subscribe